Eli Lilly and Company Receives FDA Approval for Every-Eight-Week Maintenance Dosing of EBGLYSS in Atopic Dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the ...

June 11, 2026 | Thursday | News
RedHill Pursues Collaborative Pathways to Advance Opaganib for Ebola Virus Disease

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...

June 05, 2026 | Friday | News
T-CURX Acquires Pantherna to Accelerate In Vivo CAR-T Development

T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovati...

June 03, 2026 | Wednesday | News
Intravacc and Primrose Bio Renew Strategic Alliance to Accelerate Conjugate Vaccine Development

Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has knowhow in vaccine conjugation a...

June 02, 2026 | Tuesday | News
Achieving the Promise of Biosimilars: Expanding Access, Affordability, and Healthcare Equity

As healthcare systems around the world grapple with rising costs, growing chronic disease burdens, and increasing demand for innovative therapies, biosimil...

June 01, 2026 | Monday | Interview
AIDS Healthcare Foundation Presses Shareholders to Challenge Gilead Sciences Patent Strategy at 2026 AGM with Proposal 6

With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...

April 29, 2026 | Wednesday | News
Evaxion’s AI-Designed Cancer Vaccine EVX-01 Shows Record Immune Response Rates in Phase 2 Melanoma Trial

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...

April 21, 2026 | Tuesday | News
Sanofi’s Nuvaxovid Shows Superior Tolerability vs mNEXSPIKE in Head-to-Head Study

Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase...

April 21, 2026 | Tuesday | Reports
Evaxion’s EVX-01 Shows Record 86% Immune Response Rate in Phase 2 Personalized Cancer Vaccine Study

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...

April 20, 2026 | Monday | News
Swissmedic Approves Bavarian Nordic’s VIMKUNYA®, Marking Fourth Global Authorization for Chikungunya Vaccine

Bavarian Nordic A/S announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active i...

April 17, 2026 | Friday | News
Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Platform

Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...

March 31, 2026 | Tuesday | News
Emergent BioSolutions Secures $54M U.S. Contract and Expands Global Orders for Smallpox Countermeasures

Emergent BioSolutions Inc. announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Glo...

March 27, 2026 | Friday | News
New England Biolabs Launches EnClose Kit for Rapid Cell-Free dbDNA Synthesis

New England Biolabs announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight. This novel kit enable...

March 23, 2026 | Monday | News
Bio Usawa and Nanoly Bioscience Partner to Revolutionize Biologic and Vaccine Distribution with DynaShield™

Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization,  announced a defin...

February 19, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close